PACB

+ Watchlist + Portfolio

Pacific Biosciences of California, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.27
52-Week Range: $1.07 – $2.73
Market Cap: $382.32M
P/E (TTM): —
EPS (TTM): -0.42
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -929.32%
Return on Assets: -14.07%
Gross Margin: 29.42%
Operating Margin: -114.36%
Profit Margin: -82.49%
Current Ratio: 4.92
Debt/Equity: —
Total Debt: $709.13M
Free Cash Flow: $291.64M
Revenue Growth: -1.90%
Earnings Growth: —
Enterprise Value: $867.01M

PACB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$128.30M	$200.52M	$154.01M	$160.00M
Cost of Revenue	$79.27M	$147.74M	$116.73M	$114.22M
Gross Profit	$49.03M	$52.78M	$37.28M	$45.78M
Research & Development	$193.00M	$187.17M	$134.92M	$97.31M
Selling, General & Admin	$160.85M	$169.82M	$175.02M	$141.49M
Operating Expenses	$353.85M	$363.14M	$327.94M	$603.34M
Operating Income	-$304.82M	-$310.37M	-$290.66M	-$557.56M
EBITDA	-$282.24M	-$277.28M	-$242.77M	-$152.69M
Pretax Income	-$314.25M	-$318.16M	-$309.54M	-$546.06M
Income Tax	$0.00	-$11.42M	$316.00K	$318.00K
Net Income	-$314.25M	-$306.74M	-$309.85M	-$546.38M
Diluted EPS	-1.40	-1.21	-1.58	-1.82
Diluted Shares	224.55M	253.63M	288.37M	299.96M

PACB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$325.09M	$179.91M	$55.37M	$63.71M
Receivables	$18.79M	$36.62M	$27.52M	$35.45M
Inventory	$50.38M	$56.68M	$58.76M	$49.28M
Current Assets	$852.07M	$742.05M	$495.68M	$375.05M
Total Assets	$1.77B	$1.75B	$1.26B	$784.08M
Current Liabilities	$263.33M	$95.03M	$66.30M	$72.83M
Long-Term Debt	$896.68M	$892.24M	$647.49M	$645.38M
Total Debt	$948.48M	$933.93M	$672.43M	$702.42M
Total Liabilities	$1.20B	$1.04B	$753.85M	$778.73M
Retained Earnings	-$1.53B	-$1.84B	-$2.15B	-$2.70B
Shareholders' Equity	$562.90M	$701.30M	$506.59M	$5.35M
Working Capital	$588.74M	$647.02M	$429.38M	$302.22M
Net Debt	$573.44M	$712.82M	$592.12M	$581.67M

PACB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$263.21M	-$259.17M	-$206.06M	-$111.21M
Capital Expenditure	-$16.93M	-$8.84M	-$6.19M	-$7.71M
Free Cash Flow	-$280.14M	-$268.02M	-$212.25M	-$118.92M
Depreciation & Amortisation	$17.32M	$26.53M	$53.35M	$386.41M
Stock-Based Compensation	$78.61M	$72.12M	$71.04M	$41.67M
Investing Cash Flow	$116.08M	$4.60M	$124.00M	$115.45M
Financing Cash Flow	$9.62M	$108.89M	-$42.99M	$3.43M
Net Change in Cash	-$137.51M	-$145.68M	-$125.04M	$7.67M

PACB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$37.15M	$39.77M	$38.44M	$44.65M	$37.18M
Cost of Revenue	$38.52M	$25.08M	$22.54M	$28.08M	$24.34M
Gross Profit	-$1.37M	$14.68M	$15.90M	$16.57M	$12.84M
Research & Development	$29.05M	$22.53M	$22.85M	$22.88M	$19.61M
Selling, General & Admin	$40.17M	$36.17M	$31.10M	$34.05M	$31.15M
Operating Expenses	$431.26M	$59.54M	$54.78M	$57.76M	$66.99M
Operating Income	-$432.63M	-$44.85M	-$38.88M	-$41.20M	-$54.15M
EBITDA	-$51.86M	-$35.58M	-$31.48M	-$33.78M	-$2.28M
Pretax Income	-$426.38M	-$41.90M	-$37.62M	-$40.17M	-$8.09M
Income Tax	-$302.00K	$35.00K	$383.00K	$202.00K	$184.00K
Net Income	-$426.07M	-$41.93M	-$38.00M	-$40.37M	-$8.28M
Diluted EPS	-1.44	-0.14	-0.13	-0.13	-0.03
Diluted Shares	296.86M	300.16M	300.84M	301.91M	305.82M

PACB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$58.51M	$54.80M	$56.47M	$63.71M	$56.27M
Receivables	$31.64M	$32.26M	$30.62M	$35.45M	$29.35M
Inventory	$54.01M	$53.84M	$53.15M	$49.28M	$51.02M
Current Assets	$444.92M	$413.40M	$394.24M	$375.05M	$369.52M
Total Assets	$860.79M	$825.47M	$803.16M	$784.08M	$782.37M
Current Liabilities	$66.60M	$59.75M	$63.21M	$72.83M	$65.36M
Long-Term Debt	$646.21M	$646.44M	$645.16M	$645.38M	$644.11M
Total Debt	$699.11M	$699.22M	$700.08M	$702.42M	$703.39M
Total Liabilities	$769.15M	$763.98M	$767.07M	$778.73M	$780.00M
Retained Earnings	-$2.58B	-$2.62B	-$2.65B	-$2.70B	-$2.70B
Shareholders' Equity	$91.64M	$61.49M	$36.09M	$5.35M	$2.37M
Working Capital	$378.32M	$353.64M	$331.03M	$302.22M	$304.16M
Net Debt	$587.71M	$591.63M	$588.69M	$581.67M	$587.83M

PACB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$44.06M	-$29.38M	-$18.71M	-$19.07M	-$44.69M
Capital Expenditure	-$6.39M	-$550.00K	—	-$861.00K	-$8.04M
Free Cash Flow	-$50.45M	-$29.93M	-$18.62M	-$19.93M	-$52.73M
Depreciation & Amortisation	$372.78M	$4.58M	$4.40M	$4.65M	$4.07M
Stock-Based Compensation	$9.20M	$11.89M	$10.98M	$9.59M	$4.46M
Investing Cash Flow	$45.23M	$25.28M	$18.90M	$26.03M	$35.86M
Financing Cash Flow	$1.96M	$0.00	$1.47M	$0.00	$1.44M
Net Change in Cash	$3.14M	-$4.09M	$1.66M	$6.96M	-$7.39M

Market Snapshot

About

Pacific Biosciences develops and manufactures sequencing systems for genetic analysis, specializing in long-read sequencing technology. The company produces the Sequel and Revio systems, which can read much longer DNA fragments than traditional short-read sequencing, enabling better genome assembly and detection of structural variants. Its technology is used in research, clinical diagnostics, and agricultural genomics.